Caused by the bacterium Brachyspira hyodysenteriae, swine dysentery is a production-limiting disease that leads to significant economic losses for swine producers. There’s no effective vaccine for the infectious disease, and the only treatment option is antibiotic drugs.
Finatto said pBD-5 holds promise as an alternative to traditional antibiotic treatments—an important factor in global efforts to address the growing threats of antimicrobial resistance and food security for the world’s increasing population.
“We currently need antibiotics for animal welfare reasons—we cannot let the animals suffer from treatable diseases,” said Finatto. “But the development of this novel molecule is important because it is naturally produced by the pig. We can selectively breed animals that produce more of this protein—essentially creating pigs with stronger innate immunity.”
The team’s discovery was inspired by their observations of how some pigs developed severe clinical signs of swine dysentery while others in the same herd remained relatively unaffected by the disease.
Through detailed genomic analysis, the researchers identified a region of the swine genome associated with this resilience, which encoded a peptide resembling β-defensins, a family of host defence molecules known for their antimicrobial properties.
Building on this discovery, Finatto and the team synthesized the peptide in the lab. USask researchers completed this challenging task in collaboration with chemistry scientists at the Université du Québec à Montréal. When the researchers exposed pBD-5 to various bacterial strains, the synthesized peptide demonstrated broad-spectrum antimicrobial activity—effectively inhibiting bacterial growth.
Click here to see more...